Belgium uncovers illegal cigarette factory, €6.2 million in tax losses

Oct.28.2024
Belgium uncovers illegal cigarette factory, €6.2 million in tax losses
The Belgian authorities recently dismantled the 11th illegal cigarette production facility, resulting in a loss of €6.2 million in tax revenue. In 2024, Belgium seized nearly 205 million cigarettes, which the Ministry of Finance estimates represents a tax loss of approximately €96 million.

The Belgian Finance Ministry announced on Wednesday (23 October) that authorities had dismantled the country's 11th illegal cigarette production facility this year, marking a record number of discoveries in a single year, according to the Brussels Times on 24 October.

 

Ministry spokeswoman Florence Angelici said: "We know what we've seized," confirming that rising tobacco prices have led to a general increase in demand for cheaper, illegal cigarettes. (The illicit cigarette trade often involves the production or sale of counterfeit tobacco products and untaxed cigarettes).

 

The latest raid took place at a warehouse in East Flanders, which was equipped with tobacco cutting, production and packaging lines. Belgian customs and local police seized approximately 11 tonnes of tobacco and 5.6 million Rothmans and Marlboro cigarettes, resulting in an estimated loss of €6.2 million in tax revenue.

 

A report commissioned by Philip Morris International found that around 13% of illegal cigarettes consumed in the EU last year were smoked in Belgium.

 

Angelici noted that much of the domestically produced cigarettes are not sold locally, but are smuggled to high demand countries such as the UK and France. The proximity to a booming illicit cigarette market, as well as the country's ports and extensive road networks, make Belgium "highly attractive" to those involved in production and smuggling activities.

 

In 2024, Belgium seized nearly 205 million cigarettes, which the finance ministry estimates represents a loss of tax revenue of around €96 million.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
British American Tobacco said 2026 will mark a return to its mid-term growth algorithm, but CEO Tadeu Marroco stressed that deliverywill depend heavily on enforcement against illicit vapour products in the United States. Speaking at the FY2025 results call, he positioned Modern Oral as the company’s primary structural growth engine, reframed accelerating cigarette declines through “poly-usage,” and reinforced capital discipline with an expanded share buyback plan.
Feb.12
Focus on Regulation and Taxation: EVO NXT 2026 Provides Strategic Guidance for Decision-Makers
Focus on Regulation and Taxation: EVO NXT 2026 Provides Strategic Guidance for Decision-Makers
The NGP industry faces rising innovation pressure, growing consumer demand and intensifying regulatory dynamics. Sustainable growth now depends on reliable market intelligence, strong partnerships and structured dialogue with policymakers and stakeholders. On 17–18 April 2026 in Prague, EVO NXT will convene manufacturers, retailers, distributors and industry experts for strategic exchange, with this year’s conference placing regulation and taxation firmly at the center of discussion.
Mar.02
Haypp confirms exit from UK vape category as it shifts focus to oral nicotine
Haypp confirms exit from UK vape category as it shifts focus to oral nicotine
Haypp, an online retailer of alternative nicotine products, has confirmed it is exiting the UK vape category as it shifts focus to the oral nicotine market. The company said analysis of its sales data showed increasing adoption of nicotine pouches across its six international markets: the UK, the USA, Germany, Norway, Switzerland and Sweden.
Mar.04 by 2FIRSTS.ai
Federal Register notice: FDA seeks comments on “Warning Plans for Certain Tobacco Products”
Federal Register notice: FDA seeks comments on “Warning Plans for Certain Tobacco Products”
The U.S. Food and Drug Administration (FDA) issued a notice stating it has submitted a proposed information collection to the Office of Management and Budget (OMB) for review under the Paperwork Reduction Act.
Jan.16 by 2FIRSTS.ai
France drops a vaping clause from the 2026 finance bill after use of Article 49.3
France drops a vaping clause from the 2026 finance bill after use of Article 49.3
A provision in France’s 2026 finance bill intended to regulate vaping products was abandoned after Sébastien Lecornu used Article 49.3 on January 20 to commit the government’s responsibility on the “revenue” section of the state budget.
Jan.21 by 2FIRSTS.ai